activated recombinant human factor VII + activated recombinant human factor VII
Phase 1CompletedDevelopment Stage
Acquired Bleeding Disorder
Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder, Congenital FVII Deficiency, Glanzmann's Disease, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors, Healthy
Apr 1, 2006 → Sep 1, 2006
About activated recombinant human factor VII + activated recombinant human factor VII
activated recombinant human factor VII + activated recombinant human factor VII is a phase 1 stage product being developed by Novo Nordisk for Acquired Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01561417. Target conditions include Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder.
What happened to similar drugs?
4 of 20 similar drugs in Acquired Bleeding Disorder were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01561417 | Phase 1 | Completed |
| NCT01562587 | Phase 1 | Completed |
Competing Products
20 competing products in Acquired Bleeding Disorder